HeartFlow is a medical technology company revolutionizing precision heart care.
There is no company in the world doing what we do—combining decades of human ingenuity and advanced technology in a completely novel way. We are passionate about transforming the diagnosis and management of coronary artery disease and continue to innovate, pushing into new frontiers and forging incredible partnerships along the way. Learn more about our story below.
Began development of image-based modeling for coronary blood flow
Charles Taylor PhD: expert in computational fluid dynamics at Stanford University
Christopher Zarins MD: chair of vascular surgery at Stanford University
Founded HeartFlow in Silicon Valley, California
Received U.S. FDA de novo 510(k) clearance
Commercially available in the U.S. (FFRCT First Generation)
Commercially available in Japan
> 150 peer-reviewed publications
> 150 issued and allowed patents worldwide
NICE Guidance recommends HeartFlow
> 10,000 patients worldwide have received the HeartFlow Analysis
Innovation and Technology Payment Program Awarded by NHS England
Received reimbursement approval in Japan from MHLW
Launched PRECISE Randomized Clinical Trial
FFRCT 2nd Generation Released
Named one of the World’s Most Innovative Companies by Fast Company
FDA Clearance Received for HeartFlow Planner
FORECAST trial results show increased treatment efficiency with HeartFlow Analysis
JAMA Network Open Publication Demonstrates the Coronary CT-HeartFlow Analysis Pathway is ‘Dominant’ Compared to Stress Testing in Cost-Effectiveness Analysis
FFRCT officially recognized in the 2021 ACC/AHA Chest Pain Guidelines
>500 Peer reviewed publications supporting HeartFlow FFRCT
NHS England and NHS Improvement mandate adoption of AI-powered HeartFlow Analysis to fight coronary heart disease
Completes Patient Enrollment in the PRECISE Trial
FFRCT 3rd Generation Released
FISH&CHIPS 2 Year Results
HeartFlow ONE Launched
FFRCT Transition to Category I Announced
250,000 Patients have received a HeartFlow FFRCT Analysis
While we continue to trailblaze in the field of cardiology, we are proud of our numerous accomplishments bringing us to where we are today, including more than 250,000 patients served, adoption at more than 950 hospitals worldwide, full coverage by Medicare, and 96% of commercial lives in the United States, a robust body of clinical evidence including more than 500 peer-reviewed publications, and an IP portfolio of more than 400 issued and allowed patents worldwide. We are committed to continuing to transform the diagnosis and management of coronary artery disease and are grateful for the countless collaborations today and in the future to make this vision a reality worldwide.
HeartFlow Analysis is consisted of four main functions; FFRCT, Planner, Roadmap, and Plaque. All four functions are cleared for clinical use in the United States, Bahrain, Israel, and United Arab Emirates. Only FFRCT and Planner functions are cleared cleared for clinical use in Europe, United Kingdom, Australia, Canada, and Japan. Please see HeartFlow Analysis Indications for Use and Instructions for Use for more information.
© 2024 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041
*Required fields
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
*Required fields
オンライン提出フォームから研究助成金を申請してください。
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.
If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.Please use our online submission form on the Clinical Research Page to apply for research grants.
Thank you for your interest!
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.